

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Dirk M. Anderson and Laurent J. Galibert

Docket No.:

2874-B

Group Art Unit: Unknown

Serial No: --to be assigned--

Examiner: Unknown

Filed: November 3, 2000

For: METHOD OF INHIBITING OSTEOCLAST ACTIVITY

*Pre Grant
2A
mw*PRELIMINARY AMENDMENT

BOX PATENT APPLICATION

Assistant Commissioner for Patents

Washington, D.C. 20231

Prior to examining the above-referenced patent application, please enter the following amendments into the application:

Between the Title and the Technical Field of the Invention, please insert the following paragraph:

-- This application is a continuation of PCT/US99/10588, filed May 13, 1999, which claims the benefit of priority from U.S. provisional applications 60/085,487, filed May 14, 1998, and 60/110,836, filed December 3, 1998, and is a continuation-in-part of United States patent application 08/966,139 (now U.S. 6,017,729), filed December 22, 1997, which claims the benefit of priority from U.S. provisional applications 60/064,671, filed October 14, 1997; 60/077,181, filed March 7, 1997; and 60/059,978, filed December 23, 1996. --

In the Specification:

✓ At page 3, line 31, please delete [a nucleotide]

At page 3, at line 7, between "NO:2." and "Moreover" please insert:

-- Other members of the TNF receptor superfamily have a region of amino acids between the transmembrane domain and the ligand binding domain that is referred to as a 'spacer' region, which is not necessary for ligand binding. In RANK, the amino acids between

09705985 110300

*Jul
B**Q2*